BD
BDULF.US Bangkok Dusit Medical Services Public Company Limited
- Market cap
- -
- P/E
- 16.3x
- P/B
- 2.53x
- ROE
- 14.2%
- Dividend yield
- 4.68%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BDULF.US undervalued?
Graham numberThe Graham number of Bangkok Dusit Medical Services Public Company Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bangkok Dusit Medical Services Public Company Limited fundamental analysis
No fundamental analysis for Bangkok Dusit Medical Services Public Company Limited yet.
Bangkok Dusit Medical Services Public Company Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bangkok Dusit Medical Services Public Company Limited
Bangkok Dusit Medical Services Public Company Limited, together with its subsidiaries, operates hospitals in Thailand and internationally. It operates through two segments Hospital Operations; and Other Businesses That Support Hospital Business. The company operates hospitals under the Bangkok Hospital Group, Samitivej Hospital Group, BNH Hospital, Phyathai Hospital Group, Paolo Hospital, and Royal Hospital Group names; and BDMS Wellness Clinic. It also offers medical labora…
Full company profileBangkok Dusit Medical Services Public Company Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bangkok Dusit Medical Services Public Company Limited annual financial statements (THB; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 68.0B | 71.9B | 78.4B | 82.7B | 68.1B | 74.5B | 91.9B | 101B | 108B | 111B | 110B |
| Gross Profit | 22.7B | 24.0B | 26.9B | 28.4B | 21.7B | 25.0B | 33.6B | 37.4B | 39.8B | 38.9B | 38.2B |
| Operating Income | 11.3B | 11.8B | 13.5B | 13.2B | 11.0B | 11.2B | 17.0B | 18.9B | 20.5B | 18.4B | 16.9B |
| EBITDA | 16.4B | 19.8B | 18.9B | 26.6B | 17.7B | 17.6B | 23.1B | 25.0B | 26.9B | 25.3B | 24.2B |
| Net Income | 8.39B | 10.2B | 9.19B | 15.5B | 7.21B | 7.94B | 12.6B | 14.4B | 16.0B | 15.8B | 14.6B |
| EPS | 0.54 | 0.66 | 0.59 | 0.99 | 0.45 | 0.50 | 0.79 | 0.90 | 1.01 | 1.00 | 0.92 |
| Balance Sheet | |||||||||||
| Total Assets | 107B | 123B | 133B | 134B | 136B | 128B | 142B | 144B | 152B | 158B | 157B |
| Total Liabilities | 48.6B | 56.8B | 60.1B | 46.5B | 44.6B | 40.7B | 47.8B | 44.7B | 47.6B | 47.9B | 50.2B |
| Shareholders' Equity | 55.7B | 63.1B | 70.3B | 83.8B | 87.9B | 83.8B | 89.9B | 95.4B | 100B | 106B | 103B |
| Cash & Short-term Investments | 4.22B | 5.66B | 5.85B | 5.60B | 20.9B | 12.7B | 15.0B | 9.49B | 8.72B | 7.24B | 3.91B |
| Total Debt | 31.9B | 39.3B | 39.9B | 24.4B | 24.2B | 18.8B | 23.6B | 18.1B | 18.4B | 17.5B | 19.0B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 12.4B | 10.9B | 14.8B | 14.5B | 11.7B | 14.6B | 20.3B | 20.8B | 23.0B | 23.4B | 22.3B |
| Capital Expenditure | 8.98B | 15.6B | 7.70B | 7.99B | 6.65B | 4.37B | 5.07B | 8.31B | 11.7B | 10.4B | 7.38B |
| Free Cash Flow | 3.47B | -4.67B | 7.11B | 6.55B | 5.03B | 10.2B | 15.2B | 12.5B | 11.3B | 13.0B | 14.9B |
| Ratios | |||||||||||
| ROE | 15.1% | 16.2% | 13.1% | 18.5% | 8.2% | 9.5% | 14.0% | 15.1% | 16.0% | 15.0% | 14.2% |
| ROA | 7.8% | 8.3% | 6.9% | 11.6% | 5.3% | 6.2% | 8.9% | 10.0% | 10.6% | 10.0% | 9.3% |
| Net Profit Margin | 12.3% | 14.2% | 11.7% | 18.8% | 10.6% | 10.7% | 13.7% | 14.3% | 14.8% | 14.2% | 13.3% |
| Debt to Equity | 0.57x | 0.62x | 0.57x | 0.29x | 0.28x | 0.22x | 0.26x | 0.19x | 0.18x | 0.17x | 0.18x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bangkok Dusit Medical Services Public Company Limited dividends
- Dividend yield
- 4.68%
- Forward dividend
- 0.02 USD
- Payout ratio
- 75.2%
- Ex-dividend date
- Sep 8, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | THB 11.9B | 0.75 | 75.2% |
| 2024 | THB 11.1B | 0.70 | 69.6% |
| 2023 | USD 10.3B | 0.65 | 71.9% |
| 2022 | THB 7.94B | 0.50 | 63.0% |
| 2021 | USD 12.7B | 0.80 | 160.5% |
| 2020 | USD 4.74B | 0.30 | 65.7% |
| 2019 | USD 6.94B | 0.44 | 44.7% |
| 2018 | USD 5.59B | 0.36 | 60.9% |
| 2017 | USD 4.95B | 0.32 | 48.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 10:1 on Apr 29, 2014.
Who owns Bangkok Dusit Medical Services Public Company Limited
- Insiders 0.00%
- Institutions 9.56%
- Public & others 90.44%
- Free float 12.8B
Bangkok Dusit Medical Services Public Company Limited company profile
- Company name
- Bangkok Dusit Medical Services Public Company Limited
- Ticker
- BDULF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Fiscal year end
- December
- Address
- 2, Soi Soonvijai 7, Bangkok, Thailand, 10310
- Phone
- 66 2 310 3000
- Website
- bdms.co.th
About Bangkok Dusit Medical Services Public Company Limited
Bangkok Dusit Medical Services Public Company Limited, together with its subsidiaries, operates hospitals in Thailand and internationally. It operates through two segments Hospital Operations; and Other Businesses That Support Hospital Business. The company operates hospitals under the Bangkok Hospital Group, Samitivej Hospital Group, BNH Hospital, Phyathai Hospital Group, Paolo Hospital, and Royal Hospital Group names; and BDMS Wellness Clinic. It also offers medical laboratory, holistic clinical wellness, accounting, technology and information, training, investment and asset management, air transportation, skin and aesthetics telemedicine, and genomic medicine services; operates hotels and pharmacies; provides health insurance and insurance brokerage services; retails medicine and pharmaceutical products; and distributes health products and cosmetic products, as well as facility management services. In addition, the company is involved in production and distribution of medicines, pharmaceutical products, medical equipment, and saline; real estate; e-commerce; and investment and operation of BDMS silver wellness and residence products. Bangkok Dusit Medical Services Public Company Limited was founded in 1969 and is headquartered in Bangkok, Thailand.
Bangkok Dusit Medical Services Public Company Limited management
10- Ms. Poramaporn Prasarttong-Osoth M.D.President, Senior CEO of Group 1 & Authorized Director · born 1971
- Mr. Chuladej Yossundharakul M.D.Executive Vice Chairman · born 1933
- Ms. Narumol Noi-AmSenior EVP, CFO & Authorized Director · born 1958
- Mr. Chairat Panthuraamphorn M.D.COO & Executive Director · born 1955
- Mr. Sripop SarasasChief Administration Officer & Authorized Director · born 1957
- Mr. Pradit TheekakulAuthorized Director · born 1959
- Mr. Att ThongtangExecutive Director & CEO of Group 5 · born 1975
- Ms. Ajaya IntaraprasongHead of the Investor Relations
- Ms. Daranee BunchongsilpHead of Internal Audit · born 1982
- Mr. Chokchai Jarusiripipat M.D.Chief Medical Officer